Introduction
============

After transcription, newly synthesized RNA molecules must undergo maturation steps to become functional molecules, and unnecessary RNAs are subjected to turnover. In both the RNA maturation and turnover mechanisms, enzymatic cleavage of RNA molecules plays a crucial role. When cleaved, RNAs can generally possess a hydroxyl group (OH), a phosphate (P), or a 2′,3′-cyclic phosphate (cP) at their termini. While OH and P can be found at both the 5′- and 3′-ends of RNAs, a cP presents only at the 3′-end of RNAs in which the 2′- and 3′-positions of ribose is bridged by the phosphate (Figure [1](#F1){ref-type="fig"}). Catalytic machineries of RNA cleavage determine the terminal phosphate states of the generated RNA molecules, which is not just a consequence of the cleavage, but, in many cases, is critical for further RNA maturations and functions. The current, standard RNA-sequencing (RNA-seq) methods rely on 5′-P/3′-OH ends of RNAs, and thus, RNAs with a cP (cP-containing RNAs: cP-RNAs) cannot be captured because cP end cannot be ligated to the 3′-adapter by ATP-dependent ligase. Consequently, cP-RNAs are "invisible" in RNA-seq data and therefore form a hidden component of transcriptome. However, accumulating evidence indicates that the cP-RNA generation is significant in various biological processes. Here, we summarize our knowledge of cP-RNAs' biogenesis mechanisms, expression, and molecular functions and discuss how to further interrogate cP-RNA biology.

![Chemical structures of RNA termini.](fgene-09-00562-g001){#F1}

Possible Catalytic Mechanisms of cP Formation
=============================================

There are multiple situations in which a cP is formed at the 3′-end of RNA molecules. cP frequently appears as an intermediate form during RNA cleavage by many endoribonucleases \[e.g., pancreatic ribonuclease (RNase A), RNase T~1~, and RNase T~2~\], which eventually generate RNAs with 3′-P/5′-OH ends ([@B18]; [@B52]; [@B89]). RNA cleavage by these enzymes is composed of two steps: (i) transesterification (transphosphorylation), forming an intermediate cP, and (ii) cP hydrolysis to generate a 3′-P ([@B28]; [@B71]) (Figure [2A](#F2){ref-type="fig"}). RNase A, the best studied enzyme among such endoribonucleases, contains a catalytic triad, His12, Lys41, and His119, which, especially the two histidines, serve as general acid-base catalysts during both steps ([@B101]; [@B134]; [@B17]). Step (i) is initiated with 2′-OH deprotonation by a base catalyst, His12, followed by nucleophilic attack of the phosphorus by the generated 2′-oxygen (O), which causes transesterification to form a 2′,3′-cP. His119 assists the reaction as an acid catalyst by donating a proton to the leaving group, forming a 5′-OH end. Lys41 forms a hydrogen bond with 2′-O to transiently stabilize the cP. In step (ii), to hydrolyze the cP, His119 serves as a base catalyst to remove a proton from the vicinal water molecule, while His12 serves as an acid catalyst by donating a proton to form 2′-OH, generating a 3′-P as a final form.

![cP formation via RNA cleavage by ribonucleases. **(A,B)** Cleavage reactions catalyzed by RNase A **(A)** and ANG **(B)**. **(C)** Structure of ANG catalytic site (human wild type, PDB ID: 1B1I). Three catalytic residues are shown in pink, and the residues forming a substrate binding pocket and/or associating with Gln117 are shown in green. Orange dotted lines indicate the hydrogen bonds that particularly support Gln117's obstructive position ([@B67], [@B68]; [@B44]).](fgene-09-00562-g002){#F2}

Although the above case produces a cP just as an intermediate form, many ribonucleases, as summarized in Table [1](#T1){ref-type="table"}, generate a cP as a final form via their RNA cleavage that only conducts step (i) without proceeding to step (ii) (Figure [2B](#F2){ref-type="fig"}). As a well-studied example, RNA cleavage by angiogenin (ANG), an endoribonuclease belonging to the RNase A superfamily ([@B25]; [@B117]), yields a cP end ([@B115]). ANG contains the catalytic triad, His13, Lys40, and His114, which are well-conserved among RNase A superfamily members, but shows 10^5^--10^6^-fold lower ribonucleolytic activity compared to RNase A ([@B115]; [@B40]). Certain unique structural features of ANG can explain this low catalytic activity. ANG's substrate binding pocket is obstructed by Gln117 ([@B2]; [@B103]) (Figure [2C](#F2){ref-type="fig"}), which is stabilized by a hydrogen bond with Thr44 ([@B67], [@B68]; [@B44]). Two hydrogen bonds from Asp116 and Ser118 further stabilize Gln117's obstructive position ([@B103]). These steric hindrances would cause decreased substrate accessibility, possibly leading to low cleavage and cP hydrolysis activities. Indeed, a single mutation of Gln117 to Gly showed at least a ∼20-fold increase in ribonuclease activity, as well as a ∼28-fold increase in cP hydrolysis activity ([@B103]; [@B68]). In addition, Asp116 could contribute to low cP hydrolysis activity as well as low cleavage activity. While the corresponding Asp121 of RNase A forms a hydrogen bond with catalytic His119, presumably to support its imidazole ring orientation, Asp116 of ANG does not support catalytic His114 but forms two hydrogen bonds with Ser118 ([@B68]). The lack of support for His114 should have an adverse effect on the cP hydrolysis reaction because His114 would have initiated the reaction as a base catalyst, possibly leaving a cP as a final form.

###### 

Ribonucleases reported to generate a cP as a final form.

  Ribonuclease            Type   cP-examined organism     Target RNA                             Physiological role                              Reference validating the cP formation
  ----------------------- ------ ------------------------ -------------------------------------- ----------------------------------------------- ---------------------------------------
  ANG                     Endo   Human                    Mature tRNAs                           Production of tRNA halves (tiRNAs, SHOT-RNAs)   [@B115]; [@B48]
  IreI                    Endo   Human, *S. cerevisiae*   *XBP1 (HAC1)* mRNA                     Xbp1 mRNA splicing in the UPR pathway           [@B39]; [@B121]
  PP11                    Endo   Human                    (not identified)                                                                       [@B66]
  Sen2                    Endo   *S. cerevisiae*          Precursor tRNAs containing an intron   tRNA splicing                                   [@B95]; [@B137]
  Las1                    Endo   *S. cerevisiae*          37S precursor rRNA                     rRNA maturation                                 [@B35]
  GCN4                    Endo   *S. cerevisiae*          (not identified)                                                                       [@B90]
  zymocin (γ-subunit)     Endo   *K. lactis*              tRNAs-GluUUC, LysUUU, GlnUUG           Toxin to inhibit other yeasts' growth           [@B73]
  PaT (PaOrf2)            Endo   *P. acaciae*             tRNA-GlnUUG, GlnCUG                    Toxin to inhibit other yeasts' growth           [@B62]
  MazF                    Endo   *E. coli*                mRNAs, tRNAs, rRNAs                    TA system                                       [@B152]
  ChpBK                   Endo   *E. coli*                mRNA                                   TA system                                       [@B153]
  Colicin E5              Endo   *E. coli*                tRNAs-TyrGUA, HisGUG, AsnGUU, AspGUC   Toxin to kill other bacteria                    [@B92], [@B91]
  Colicin D               Endo   *E. coli*                tRNAs-ArgACG,ArgCCG, ArgUCU, ArgCCU    Toxin to kill other bacteria                    [@B135]
  prrC                    Endo   *E. coli*                tRNA-LysUUU                            Host defense upon phase infection               [@B3]
  NendoU                  Endo   Nidovirus                (not identified)                                                                       [@B53]
  Type IB topoisomerase   Endo   Vaccinia virus           (not identified)                                                                       [@B113]; [@B122]
  USB1 (MPN1)             Exo    Human                    U6 snRNA                               U6 snRNA maturation                             [@B85]

Nomenclatures of ribonucleases are according to the organisms examined and reported. PP11, placental Protein 11; GCN4, general control protein 4; Endo, endoribonuclease; and Exo, exoribonuclease

.

RNA cleavage by colicin E5, a cytotoxic endoribonuclease found in *Escherichia coli*, also yields a cP as a final form ([@B92]; [@B91]), presumably due to cP structure stabilization. The ribonuclease domain of colicin E5 does not contain histidines, the most frequently utilized catalytic residues ([@B5]), but possesses Arg33 and Lys25 (numbering from C-terminal domain) as catalytic residues ([@B144]; [@B51]). Although the catalytic mechanism remains to be further examined, these residues, along with Ile94 that supports the orientation of Arg33, might stabilize a cP structure ([@B51]), which would contribute to generating a cP as a final form. A cP structure may also be stabilized through interaction with a protein during RNA cleavage of a eukaryotic cP-forming exoribonuclease, U six biogenesis protein 1 (USB1), also known as mutated in poikiloderma with neutropenia protein 1 (MPN1). USB1 contains two well-conserved His-x-Ser (HxS) catalytic motifs in the active site cleft ([@B85]; [@B43]). It is speculated that, while His120 and His208 in these motifs serve as general acid-base catalysts, Ser122 and Ser210 in these motifs coordinate the oxygens in a cP after transesterification, potentially stabilizing a cP structure as a final form by preventing further hydrolysis.

While cP end is predominantly formed by ribonuclease-catalyzed transesterification, RNA 3′-terminal phosphate cyclase (RtcA) can catalyze *de novo* cP formation by a distinct molecular mechanism involving the following three steps ([@B36], [@B37]; [@B7]; [@B31]). First, RtcA is autoadenylylated with ATP to form a covalent RtcA-AMP intermediate. The autoadenylylation is initiated by a His309 (in *E. coli* RtcA; His320 in human RtcA)-mediated nucleophilic attack of ATP α-phosphorus, followed by covalent bond formation and pyrophosphate (PPi) release. Second, the holoenzyme then transfers the AMP to 3′-P of the substrate RNA to form an RNA with 3′-PP-5′A. Third, the energetically unstable phosphoanhydride bond between the two phosphates is cleaved by 2′-OH-mediated attack, resulting in cP formation and releasing AMP.

cP-Forming Enzymes
==================

Ribonucleases
-------------

Although the detailed molecular basis of cP formation remains to be determined, RNA cleavage by many ribonucleases produces a cP as a final, predominant form, generating cP-RNAs (Table [1](#T1){ref-type="table"}). A tRNA splicing endonuclease is one of the oldest ribonucleases known to generate cP-RNAs ([@B1]; [@B50]; [@B148]). In eukaryotes, precursors of some tRNAs, such as tRNA^LeuCAA^, tRNA^IleUAU^, and tRNA^TyrGUA^, contain an intronic region within their anticodon-loop ([@B14]). Although the splicing activity to remove tRNA introns and cP formations during the splicing were discovered in the early 1980s ([@B95]), many years and much effort were required to identify tRNA-splicing endonuclease subunit 2 (Sen2) as the endoribonuclease directly responsible for tRNA splicing ([@B137]; [@B94]; [@B96]), partly due to its membrane association property and low cellular expression level. Sen2 is a subunit of the heterotetrameric SEN complex and cleaves the 5′-splice site of tRNAs to leave a cP at the 3′-end of 5′-exons (Figure [3A](#F3){ref-type="fig"}), whereas the 3′-splice site is cleaved by Sen34. As expected from its crucial role in tRNA splicing, *SEN2* is an essential gene in yeast ([@B137]). In humans, *SEN2* gene mutations are associated with pontocerebellar hypoplasia ([@B9]; [@B87]; [@B6]).

![Generation of cP-RNAs in tRNA splicing **(A)**, tiRNA/SHOT-RNA production **(B)**, U6 snRNA maturation **(C)**, the UPR pathway **(D)**, toxin invasions **(E)**, the TA system **(F)**, and the biogenesis of tRNA-derived piRNAs **(G)**.](fgene-09-00562-g003){#F3}

Angiogenin, originally identified as a protein factor promoting angiogenesis ([@B29]; [@B65]; [@B126]), is another ancient enzyme that produces cP-RNAs ([@B115]). ANG has diverse physiological roles and is associated with various pathological conditions such as cancers and neurodegenerative diseases ([@B130]; [@B34]; [@B117]). tRNAs were identified as major endogenous RNA targets of ANG in *Xenopus* oocytes ([@B106]), and, subsequently, ANG-mediated cleavages of tRNA anticodon-loops were reported to generate functional tRNA half molecules in human cell lines ([@B33]; [@B145]; [@B48]) (Figure [3B](#F3){ref-type="fig"}). In hormone-dependent cancer cells, ANG cleavage has been shown to occur for mature aminoacylated tRNAs, generating 5′-tRNA halves with a 5′-P and a 3′-terminal cP, and 3′-tRNA halves with a 5′-OH and a 3′-terminal amino acid ([@B48]). Although *ANG* homologs are only found in vertebrates ([@B15]; [@B117]), 5′-tRNA halves expressed in *Bombyx mori* cells still contain a cP ([@B45]), suggesting that, even in the absence of *ANG* homologs, those organisms express an unidentified cP-forming endoribonuclease to cleave tRNAs and generate tRNA halves as cP-RNAs.

In vertebrates, U6 snRNA mostly contains a cP ([@B75]), whereas all other snRNAs do not ([@B78]). During maturation of U6 snRNA, several uridines are added to the 3′-end of a precursor RNA by terminal uridylyl transferase 1 (TUT1). Subsequently, USB1 (also known as MPN1), a cP-forming 3′ to 5′ exoribonuclease, excises a 3′-terminal uridine stretch to generate a mature 3′-end with four or five uridines containing a cP ([@B116]; [@B84]; [@B21]) (Figure [3C](#F3){ref-type="fig"}). Although USB1 belongs to the 2H phosphoesterase superfamily and contains a cyclic phosphodiesterase (CPDase) motif ([@B88]; [@B79]; [@B86]), human USB1 lacks the CPDase activity and thus generates a cP as a final form. In contrast, yeast Usb1 retains the CPDase activity ([@B22]), generating 3′-P end of U6 snRNA ([@B75]). It will be intriguing to address how and why the difference arose.

rRNA maturation requires a cP-forming endoribonuclease, Lethal in the absence of Ssd1 (Las1 in yeast; Las1L in human) ([@B12]; [@B110]). In yeast, rRNA maturation starts from processing of a nascent 37S rRNA precursor into shorter precursors, including 27S rRNA ([@B42]; [@B38]). The 27S rRNA is further cleaved by Las1 between 5.8S and 25S rRNA sequences, generating 7S rRNA as a 5′-cleavage product with a cP ([@B35]; [@B97]). The cleavage is catalyzed by an N-terminal α-helical 'higher eukaryotes and prokaryotes nucleotide-binding' (HEPN) domain of Las1, which has been defined as a conserved RΦxxxH catalytic motif (Φ: N, D, or H) ([@B4]; [@B97]). During further processing of 7S rRNA into mature 5.8S rRNA, a cP end of 7S rRNA is removed and processed by unknown mechanisms; therefore, cP is absent in mature rRNAs.

cP is also formed in a mRNA splicing event that plays a crucial role in activating the unfolded protein response (UPR) pathway upon endoplasmic reticulum (ER) stress. Inositol-requiring enzyme 1 (Ire1), a cP-forming endonuclease, is associated with the ER membrane with its C-terminal domain exposed to the cytosol ([@B139]; [@B151]). While an interaction with 'binding immunoglobulin protein' (BiP), an ER chaperon protein, retains Ire1 as an inactive monomer under normal conditions, ER stress releases BiP, allowing Ire1 to form a homodimer that harbors an active nuclease domain. The activated Ire1 is involved in splicing of *HAC1* mRNA (in yeast; *XBP1* mRNA in human) by cleaving both 5′- and 3′-splice sites, in which a cP is formed at the conserved 3′-terminal G of 5′-cleavage products ([@B123]; [@B39]; [@B121]) (Figure [3D](#F3){ref-type="fig"}). From the spliced, mature form of *HAC1* mRNA, a basic-region leucine-zipper transcription factor HAC1 is expressed, eventually promoting the transcription of its target genes containing UPR-responsive elements ([@B123]; [@B139]; [@B151]).

cP-forming endoribonucleases are further found in colicins, toxic proteins that are encoded in plasmid DNAs in some *E. coli* strains to invade and kill other bacteria ([@B11]). Among over 20 colicins identified thus far, colicin E5 and D have been shown to cleave the anticodon-loop of tRNAs and form a cP ([@B92]; [@B91]) (Figure [3E](#F3){ref-type="fig"}). While endoribonuclease activity of those colicins is masked by immunity proteins in host *E. coli*, colicin E5 invades other bacteria and cleaves tRNA^TyrGUA^, tRNA^HisGUG^, tRNA^AsnGUU^, and tRNA^AspGUC^ between G at nucleotide position 34 (G~34~) and U~35~ ([@B92], [@B91]), and colicin D cleaves all four isoacceptors of tRNA^Arg^ between A~38~ and G~39~/C~39~ ([@B135]), contributing to bacterial lethality.

The *E. coli* genome also encodes cP-forming endoribonucleases involved in toxin-antitoxin (TA) systems. TA systems involve bacterial stress responses, often considered "suicidal programs," comprising a stable toxin and an unstable antitoxin that neutralizes the cognate toxin in cells ([@B138]). In the well-studied MazEF system (Figure [3F](#F3){ref-type="fig"}), toxic endoribonuclease MazF is neutralized by antitoxin MazE under normal conditions, but various stresses, such as nutrient limitation, DNA damage, and antibiotic exposure, degrade MazE and thereby release MazF ([@B56]; [@B147]; [@B27]) which cleaves whole cellular mRNAs to prevent further protein production ([@B154]). MazF cleaves the 5′-side of an ACA motif within mRNAs, and forms a cP ([@B154], [@B152]; [@B140]). Recent reports showed MazF-catalyzed cleavage of 16S and 23S rRNAs, and some tRNAs such as tRNA^LysUUU^ ([@B140]; [@B82]; [@B108]; [@B109], [@B107]; [@B81]), indicating that MazF is a critical suicide factor causing perturbation of the whole cellular transcriptome. The ChpBIK system, another TA system, also uses a cP-forming enzyme as a toxin. When released from antitoxin ChpBI under stress conditions, toxic endoribonuclease ChpBK cleaves mRNAs at the 5′- or 3′-side of A in an ACY sequence motif to prevent further protein production ([@B16]; [@B153]). The 5′-cleavage products contain.

The genome of some *E. coli* isolates possesses a *prr* locus, encoding PrrC endonuclease (also known as anticodon nuclease: ACNase), which is considered to be another bacterial suicide program ([@B58]). PrrC activity is usually silenced by interaction with a masking protein, but, upon T4 phage infection, it forms an ACNase complex and cleaves tRNA^LysUUU^ between U~33~ and U~34~, which serve as a host defense to inhibit translation of T4 proteins ([@B3]; [@B83]). The 5′-tRNA^LysUUU^ half resulting from the PrrC cleavage harbors a cP.

cP-forming cytotoxic endoribonucleases are also present in eukaryotes. Zymocin and PaT are toxin complexes secreted by the yeasts *Kluyveromyces lactis* and *Pichia acaciae*, respectively, to inhibit the growth of other yeasts ([@B73], [@B72]; [@B62]) (Figure [3E](#F3){ref-type="fig"}). Zymocin is composed of the three subunits; two of them assist target cell binding and invasion, while the remaining γ-subunit cleaves tRNAs in targeted yeasts ([@B125]). The γ-subunit of zymocin recognizes a 5-methoxycarbonylmethyl-2-thiouridine (mcm^5^s^2^U), a specific modified RNA nucleotide present at np 34 of tRNA^GluUUC^, tRNA^LysUUU^, and tRNA^GlnUUG^, and cleaves between U~34~ and U~35~ of those tRNAs ([@B73]), leaving a cP at the ribose of mcm^5^s^2^U in the cleavage products. PaT is a heterodimer composed of PaOrf1, a cell invasion-assisting subunit, and PaOrf2, an endonuclease subunit ([@B80]; [@B63]). PaOrf2 recognizes 5-methoxycarbonylmethyl uridine (mcm^5^U) and cleaves between U~34~ and U~35~ of tRNA^GlnUUG^, leaving a cP at the ribose of mcm^5^U in the cleavage product ([@B62]; [@B13]).

cP-forming endoribonucleases are further found in viruses. DNA topoisomerase, encoded in vaccinia virus, belongs to the type IB family of eukaryotic DNA topoisomerases and uniquely harbors endoribonucleolytic activity, which forms a cP end at the cleaved RNAs ([@B113]; [@B122]). Analogous to yeast topoisomerase I, which can remove single ribonucleotides in DNA duplexes ([@B60]), topoisomerase's RNA cleavage activity might be involved in maintaining genome integrity during DNA replication. Replicative nidoviral uridylate-specific endoribonuclease (NendoU), encoded in nidovirus, is also a cP-forming endoribonuclease ([@B53]). While the functional role of the endoribonuclease activity in virus infection and replication is not fully understood, NendoU preferentially targets dsRNA and cleaves the 5′-side of uridine in G--U or G--U--U sequence to generate cP-RNAs ([@B53]).

Ribozymes
---------

Ribozymes are another cP-yielding biocatalyst. Among several distinct classes of ribozymes, a class of small, self-cleaving ribozymes is known to generate cPs ([@B112]; [@B23]; [@B114]). Small self-cleaving ribozymes are widely found in bacterial, plant, and mammalian genomes, and are involved in gene controls and expressions ([@B120]; [@B114]). Out of 11 identified ribozymes in this class, 10 have been shown to form cP ends as a result of their cleavage of RNAs ([@B105]; [@B112]; [@B143]; [@B104]; [@B102]; [@B41]; [@B69]; [@B142]). In the case of the hepatitis delta virus (HDV) ribozyme, the 85-nt minimal self-cleavage domain cleaves between U~−1~ and G~1~ ([@B120]; [@B100]). While C~75~ is suggested to act as a general acid catalyst by donating a proton from its N3 in the pyrimidine ring to a leaving group, several different molecules have been proposed as potential base catalysts: water or hydroxide from the solvent, water molecules coordinated to the Mg^2+^, or 2′-OH of G~27~ positioned closely adjacent to the catalytic site ([@B141]).

Enzymes That Act Directly on the 3′-End of RNAs
-----------------------------------------------

There are two protein catalysts that have been reported to form a cP by a distinct molecular mechanism from transesterification during RNA cleavage. As described above, RtcA can catalyze *de novo* cP formation by directly acting on the 3′-end of RNAs ([@B36], [@B37]; [@B7]; [@B31]). Although endogenous RNA target of RtcA is unknown, in the *E. coli* genome, *rtcA* and an RNA ligase *rtcB* form an *rtcBA* operon, which is implicated in RNA repair pathway ([@B19]; [@B10]). Archaeal thermophilic RNA ligase from *Methanobacterium thermoautotrophicum*, MthRnl, is the other enzyme which can also catalyze *de novo* cP formation ([@B156]; [@B149]). While MthRnl can ligate 5′-P and 3′-OH ends of RNAs ([@B136]), when substrate RNAs contain a 3′-P, MthRnl coverts it to a 3′-cP by a similar mechanism with RtcA ([@B156]). In addition, MthRnl possesses the 3′-deadenylation activity which can remove a 3′-terminal adenosine with an OH end and form a cP ([@B149]). Endogenous RNA target of MthRnl is unknown.

Biological Significance of cP Formation and cP-Rna Expression
=============================================================

What is the significance of cP formation in RNAs? It has been shown that cP formation in U6 snRNA regulates RNA interaction with protein factors. While nascent U6 snRNA containing 3′-OH end is bound by La protein ([@B78]; [@B77]), cP formation of mature U6 snRNA promotes interaction with Lsm2--8 complexes ([@B59]; [@B70]) (Figure [3C](#F3){ref-type="fig"}). The affinity of the cP-containing RNA to Lsm2--8 is higher than 3′-OH-containing RNA, and the interaction of La/3′-OH and Lsm2--8/cP is mutually exclusive: even when both La and Lsm2--8 exist in the reaction solution, RNA with 3′-OH or with cP only binds to La or Lsm2--8, respectively ([@B70]). cP formation is, therefore, a critical factor for forming functional spliceosome complexes with Lsm2--8 ([@B21]). Although this is the only proven example of the cP-regulated formation of RNA-protein complex, cP formation in other cP-RNAs may modulate RNA interaction with protein factors.

RNA ligation reaction can depend on a cP in a substrate RNA. In tRNA splicing, Sen2-mediated cleavage forms a 3′-terminal cP in 5′-exons, which is then ligated to the 5′-OH end of 3′-exons by tRNA ligase ([@B99]; [@B148]) (Figure [3A](#F3){ref-type="fig"}). In *Arabidopsis thaliana*, the tRNA ligase AtRNL is able to ligate cP ends to 3′-exons but cannot use 3′-P ends as its ligation substrate ([@B111]; [@B127]). This cP-specific ligation activity was also observed in wheat germ extract ([@B64]). In this plant ligation process, cP ends of 5′-exons are first converted to 2′-P and 3′-OH. 5′-OH ends of 3′-exons are phosphorylated, followed by ligation to 3′-OH of 5′-exons ([@B99]; [@B148]). Other organisms employ distinct molecular mechanisms in ligation of cP-containing 5′-exons to 3′-exons in tRNA splicing ([@B99]; [@B148]). In humans, RtcB was identified as a tRNA ligase ([@B98]). Experiments using lysates and RtcB immunoprecipitates from HeLa cells suggest that human RtcB prefers cP and 5′-OH for ligation ([@B32]; [@B98]). However, whether the substrate specificity extends to 3′-P and 5′-OH containing RNA still awaits analysis using a recombinant human tRNA ligase complex. In mammals, RtcB is involved in splicing of *XBP1* mRNA in the UPR pathway ([@B30]; [@B57]; [@B74]) (Figure [3D](#F3){ref-type="fig"}). *E. coli* RtcB is also able to ligate cP and 5′-OH, as well as 3′-P and 5′-OH ([@B129]; [@B128]). In the ligation, cP is first converted to 3′-P, then ligated to 5′-OH ([@B127]). *E. coli* RtcB can catalyze the re-ligation of 16S rRNA at the site cleaved by stress-induced MazF activity, which generates full-length 16S rRNA and contributes to restoration from the stress conditions ([@B132]).

Besides influencing interaction and activity of proteins, cP formation may play a role in stabilizing RNA molecules by protecting them from degradation. Ehrlich exoribonuclease extracted from Ehrlich ascites cells and various mouse tissues, later defined as exoribonuclease II, was shown to degrade single-stranded RNAs with 3′-OH ends more rapidly than those with cP and 3′-P ends ([@B124]), suggesting that cP formation is advantageous for RNA molecules to exist stably in cells. In contrast, because RNAs with 3′-P ends are more rapidly degraded by the exosome complex exoribonuclease, Rrp44, than those with 3′-OH ends ([@B157]), cP formation could also negatively impact the stability of cP-RNAs. Thus, a cP structure might be able to regulate RNA stability in both directions by affecting degradation activity of nucleases or modulating RNA-protein interactions. Further study is required to shed more light on the potential function of cP formation in RNA stability.

The above described advantages of cP formation may, in turn, suggest the biological significance of cellular cP-RNA expression. While the functional significance of U6 snRNA, which belongs to cP-RNAs, or tRNAs and rRNAs, whose biogenesis is intermediated by cP-RNAs, have been apparent for a long time, previously uncharacterized cP-RNAs are now being demonstrated as functional molecules which play important roles in various biological processes. Representative examples of such functional cP-RNAs include the 5′-tRNA half molecules. In mammalian cells, various stress stimuli trigger ANG-mediated tRNA cleavage to produce functional tRNA halves, termed tRNA-derived stress-induced RNAs (tiRNAs) ([@B33]; [@B145]) (Figure [3B](#F3){ref-type="fig"}). 5′-tiRNAs, corresponding to 5′-tRNA halves, have been shown as functional molecules that can promote formation of stress granules and regulate translation via YB-1 protein-involved pathway ([@B26]; [@B54], [@B55]; [@B76]).

ANG-mediated tRNA cleavage is also promoted by sex hormone signaling pathways in hormone dependent breast and prostate cancer cells, generating a distinct class of tRNA halves termed sex hormone-dependent tRNA-derived RNAs (SHOT-RNAs) ([@B48]; [@B47]) (Figure [3B](#F3){ref-type="fig"}). 5′-SHOT-RNAs, belonging to cP-RNAs, promote cell proliferation. The expression levels of SHOT-RNAs in tissues and serum of prostate cancer patients have been shown to be associated with pathological and prognostic parameters, suggesting the use of SHOT-RNAs as potential diagnostic biomarkers ([@B155]). In terms of diseases, many different *ANG* gene mutations have been identified in patients with amyotrophic lateral sclerosis (ALS) and Parkinson's disease ([@B130]; [@B34]), implying that ANG-catalyzed production of tRNA halves could be involved in the pathogenesis of these neurodegenerative disorders ([@B133]). Indeed, accumulation of tRNA halves contributes to the pathogenesis of a syndromic form of intellectual disability and Dubowitz-like syndrome ([@B8]).

cP-RNAs can also function as direct precursors for shorter functional RNAs. In *B. mori* germ cells, some abundant species of Piwi-interacting RNAs (piRNAs), a germline-specific class of small regulatory RNAs, are produced directly from cP-containing 5′-tRNA halves ([@B45]) (Figure [3G](#F3){ref-type="fig"}). Although many microRNAs (miRNAs) are derived from tRNAs ([@B119]; [@B131]), whether the tRNA-derived miRNAs are also generated from cP-containing tRNA halves has not been examined yet. Further research may reveal more evidence of cP-RNA uses as direct precursors for functional RNAs.

Specific Sequencing and Quantification of cP-Rnas
=================================================

To further expand cP-RNA research, it is imperative to capture cP-RNA expression profiles accurately, which is not possible using standard RNA-seq methods. Specific cP-RNA sequencing can be achieved by cP-RNA-seq ([@B48], [@B49]) which takes advantage of distinct properties of two well-used enzymes, T4 polynucleotide kinase (T4 PNK) and a phosphatase such as calf intestinal phosphatase (CIP). T4 PNK has 3′-terminal phosphatase activity that removes both a P and cP from the 3′-end of RNAs ([@B3]; [@B20]), whereas CIP removes only a P but not a cP. In cP-RNA-seq, RNAs are first treated with CIP to remove a P, followed by periodate oxidization. Because the oxidation cleaves the 3′-end of all RNAs other than cP-RNAs, subsequent cP removal, adapter ligation, and cDNA amplification steps are exclusively applied to cP-RNAs, leading to selective amplification and sequencing of cP-RNAs ([@B48], [@B49]) (Figure [4A](#F4){ref-type="fig"}). cP-RNA-seq only requires commercially available enzymes and reagents, which is an advantage of the method. As a limitation of the method, RNAs lacking a 2′,3′-diol structure of ribose, such as plant miRNAs and animal piRNAs that contain 2′-*O*-methyl ribose modification ([@B146]; [@B61]; [@B93]), can also be amplified despite the absence of a cP, because those RNAs would be resistant to periodate oxidation. This point should always be remembered especially when 20--30-nt small RNAs are used for the method. Thus far, cP-RNA-seq has been applied only to the two cell lines, human BT-474 breast cancer cells and *B. mori* BmN4 cells ([@B48], [@B45]). Although high mapping ratio of the obtained reads to tRNA sequences showed the specificity and credibility of the method, both of the studies narrowly focused on short RNA fraction containing tRNA haves. Further application of the method to broader RNA populations will enable more global identification of cP-RNA species.

![Schematic representation of cP-RNA-seq **(A)** and probe-based RT-qPCR **(B)** for specific cP-RNA analyses.](fgene-09-00562-g004){#F4}

As an alternative method, *Arabidopsis* tRNA ligase AtRNL can be used for specific cP-RNA sequencing ([@B111]). Because its ligation activity is specific to a cP but not to a 3′-P and 3′-OH, AtRNL selectively ligates a 3′-adapter to cP-RNAs among all RNA species. After the ligation, for efficient reverse transcription, a 2′-P formed at the substrate--adapter junction should be removed by 2′-phosphotransferase treatment. Therefore, two specific recombinant proteins, AtRNL and *Saccharomyces cerevisiae* 2′-phosphotransferase Tpt1, were purified and used in the method ([@B111]). Application of the method to human brain total RNA identified numerous reads of cP-RNAs containing U6 snRNA. The 3′-ends of ∼90% of the U6 snRNA reads were identified as a consistent, mature form, validating the specificity and credibility of the method. Considering the ligation activity for cP-RNAs, RtcB can also be used for cP-RNA sequencing ([@B24]). Because RtcB can ligate 3′-P ends, as well as cP ends, a phosphatase treatment to remove 3′-P prior to RtcB-mediated 3′-adaptor ligation would be required for specific capture of cP-RNAs.

After cP-RNA sequencing, amplification and quantification of the representative identified cP-RNA species are necessary to validate their expression and analyze whether a cP end is the major 3′-end form of the identified sequences. Standard RT-qPCR, amplifying internal sequences of targeted RNAs, is inappropriate for specific amplification of cP-RNAs because it cannot distinguish between cP-RNAs and RNAs with other terminal states. To specifically analyze cP-RNAs, RNAs treated with T4 PNK or CIP can be subjected to 3′-adapter ligation, followed by TaqMan RT-qPCR targeting 3′-adapter-RNA ligation products ([@B46]; [@B48], [@B45]; [@B118]; [@B155]) (Figure [4B](#F4){ref-type="fig"}). The dependency of amplification signals on RNA treatment with T4 PNK, but not with CIP, allows researchers to confirm that the detected signals are derived from cP-RNAs because they should be ligated to a 3′-adapter only after cP removal by T4 PNK treatment. As an alternative method for analyzing cP ends, T4 PNK- or CIP-treated RNAs can be subjected to a poly (A) polymerase reaction which is able to add poly (A) tails to 3′-OH ends, but not to cP ends ([@B150]). Moreover, northern blot can be used to observe slight differences in band mobility between cP-RNAs and RNAs with other terminal states ([@B48], [@B49]).

Future Perspectives
===================

Despite the findings described in this review, current information regarding cellular expression profiles of cP-RNAs is very limited and fragmented. Although increasing accumulation of RNA-seq data has accelerated the comparative analyses of transcriptomes and, therefore, been critical to identifying significant RNA species in biological phenomena and diseases, the "invisibility" of cP-RNA expression in RNA-seq data makes cP-RNA research be still at an initial stage. The immediate future focus should be on capturing the comprehensive repertoire of cP-RNAs expressed in different tissues and cells by using the above described specific sequencing methods. Given that cP-RNAs are expressed as functional molecules, capturing the entire cP-RNA repertoire would broaden the catalog of functional non-coding RNAs and could reveal significant biological events that have been eluding standard RNA-seq. Besides cP-RNA expression, molecular mechanisms behind cP-RNA biogenesis and function still remain elusive. Presumably, not all cP-RNA-producing enzymes have been identified and characterized to date. Because determining cP-RNA-generating enzymes only by their amino-acid sequences and protein motifs is impossible, discovering novel cP-RNA-generating enzymes will rely on detailed structural and biochemical characterizations of each enzyme. Given the already-proven biological roles of cP formation and cP-RNA expression, it is not surprising that cP-RNAs are involved in a wide range of biological processes. Considering the "hidden" nature of cP-RNAs in conventional RNA-seq data, further research efforts to characterize cP-RNAs would likely clarify substantially greater biological significance of cP-RNAs, which will advance our understanding of the expanding realm of non-coding RNA molecules.
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